<DOC>
	<DOCNO>NCT02955823</DOCNO>
	<brief_summary>A phase II study evaluate combination Lenalidomide Rituximab front line therapy treatment elderly frail patient evaluate CGA Diffuse Large B-cells non-Hodgkin Lymphoma .</brief_summary>
	<brief_title>A Combination Lenalidomide Rituximab Front Line Therapy Treatment Elderly Frail Patients Evaluated CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma . A Phase II Study Fondazione Italiana Linfomi ( FIL )</brief_title>
	<detailed_description>This prospective , multicenter , single arm , phase II trial elderly patient ( ≥ 70 year ) affect DLBCL define frail accord CGA previously untreated . The primary endpoint evaluate efficacy R2 ( Revlimid+Rituximab ) combination first line DLBCL patient candidate standard R-CHOP ( R-CHOP like ) treatment due frail status .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Histologically proven CD20 positive Diffuse Large Bcell Lymphoma accord WHO classification ( local pathologist ) 2 . Age ≥ 70 year 3 . Previously untreated 4 . CGA assessment perform start treatment 5 . FRAIL patient define follow Age &gt; 80 year : ADL &gt; 5 residual function IADL &gt; 6 residual function CIRS : 58 comorbidities grade 2 Age &lt; 80 : ADL ≤ 4 residual function IADL ≤ 5 residual function CIRS : comorbidities grade 34 &gt; 8 comorbidities grade 2 6 . Ann Arbor Stage I IV ( Appendix F ) 7 . At least one bidimensionally measurable lesion define &gt; 1.5 cm large dimension CT scan 8 . ECOG performance status 0 3 ( Appendix E ) 9 . No active hepatitis C virus ( HCV ) infection . In case HCV positivity HCVRNA require . Only patient HCVRNA negative accept . 10 . Adequate hematologic function ( unless cause bone marrow infiltrate ) , define follow : Hemoglobin &gt; 10 g/dL WBC &gt; 2500/mmc PMN &gt; 1000/ mmc Platelets count ≥ 75000/mmc Creatinine clearance ≥ 10 mL/min 11 . Ability willingness comply study protocol procedure 12 . Life expectancy &gt; 6 month 13 . Patients must give write informed consent . 14 . Male subject must practice complete abstinence agree use condom sexual contact pregnant female female childbearing potential participating study , dose interruption least 28 day follow investigational product discontinuation , even undergone successful vasectomy . 1 . Histological diagnosis different CD20 positive Diffuse Large Bcell Lymphoma exclude . 2 . Previous exposure cytotoxic agent 3 . Suspect clinical evidence CNS involvement lymphoma 4 . Contraindication use Rituximab Lenalidomide 5 . HBsAg positivitv ; HBcAb positivity accept concomitant treatment Lamivudine Tenofovir depend HBVDNA 6 . HIV positivity 7 . Any history malignancy within 5 year prior study entry except adequately treat carcinoma situ cervix basal squamous cell skin cancer 8 . AST /ALT &gt; 2 x UNL ; bilirubin &gt; 2 x UNL ; serum creatinine &gt; 2.5 mg /dL 9 . Creatinine clearance &lt; 10 mL/min 10 . Evidence severe active acute chronic infection 11 . Severe cardiac dysfunction ( NYHA grade IIIIV ) 12 . Any coexist medical psychological condition would preclude participation study compromise ability give inform consent 13 . Absence caregiver nonautonomous patient</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>B cell Lymphoma</keyword>
	<keyword>non-Hodgkin Lymphoma</keyword>
	<keyword>Elderly patient</keyword>
</DOC>